Insights

More Articles Back to Article

Venetoclax gains MHRA nod to treat newly diagnosed AML

AbbVie and Roche's Venclyxto, or venetoclax, combined with a hypomethylating agent, has been approved by the UK's Medicines and Healthcare products Regulatory Agency to treat patients newly diagnosed with acute myeloid leukemia who are not eligible for intensive chemotherapy. PharmaTimes online (UK) (6/11)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!